Loading...
XHKG
1066
Market cap1.82bUSD
Jul 10, Last price  
3.29HKD
1D
2.49%
1Q
-11.56%
Jan 2017
-36.49%
IPO
1,780.00%
Name

Shandong Weigao Group Medical Polymer Co

Chart & Performance

D1W1MN
XHKG:1066 chart
P/E
7.86
P/S
0.95
EPS
0.36
Div Yield, %
7.49%
Shrs. gr., 5y
0.20%
Rev. gr., 5y
2.87%
Revenues
13.39b
+2.31%
786,926,0001,095,109,0001,514,367,0001,878,495,0002,462,557,0003,180,577,0003,689,115,0004,613,310,0005,277,827,0005,918,930,0006,730,340,0006,292,641,0008,808,861,00010,364,081,00011,622,337,00013,151,719,00013,619,007,00013,229,453,00013,087,071,00013,388,890,000
Net income
1.61b
-21.99%
182,603,000329,342,000482,394,000633,864,000799,072,0003,462,172,000996,486,000387,984,0001,084,948,0001,112,736,0001,105,933,0001,303,162,0001,472,935,0001,844,883,0002,086,783,0002,275,929,0002,764,093,0002,001,906,0002,066,668,0001,612,210,000
CFO
2.55b
-8.58%
176,547,000276,211,000437,482,000479,074,000523,511,000620,792,000806,031,000720,174,000711,219,0001,052,770,0001,053,139,0001,443,889,6452,219,196,0002,320,990,0002,696,608,0003,035,163,0002,214,574,0002,798,529,0002,789,971,0002,550,606,000
Dividend
Jun 02, 20260.06800188 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shandong Weigao Group Medical Polymer Company Limited, established in 2000 and based in Weihai, People's Republic of China, is primarily engaged in the research, development, manufacturing, and distribution of disposable medical products within the PRC and for export. The company operates through several specialized divisions: Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and other related ventures. Its comprehensive product range includes a vast array of single-use clinical items such as vascular and non-vascular access devices (e.g., infusion sets, syringes, various puncture needles), along with specialized collection kits. It also provides solutions for wound care, encompassing sutures, dressings, and cleaning products, as well as support systems for nonvascular catheters used in extracorporeal procedures. In the critical area of blood management, Shandong Weigao supplies equipment for blood collection, storage, separation, and sterilization, in addition to prefilled and flush syringes, and devices for blood collection and glucose testing. Furthermore, its portfolio extends to anesthesia consumables for general, local, and auxiliary applications, intensive care unit (ICU) equipment, and surgical instruments designed for both open and minimally invasive operations. The company also produces orthopedic devices, interventional tools for treating tumors and vascular conditions, various implantation materials, artificial organs, and medical-grade packaging components like PVC granules, plastic bags, and carton boxes. Industrial automation equipment, parts, molds, and hemodialysis apparatus, spanning Type I, Type II, and Type III medical devices, are also part of their extensive offerings. Beyond its core manufacturing activities, the company diversifies into finance leasing and factoring, wholesale distribution of specific medical and surgical disposables, asset management, and offers enterprise consulting and management advisory services, alongside logistics and storage solutions. Its products are marketed under well-known brands such as Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing, serving a broad client base including hospitals, blood banks, other medical facilities, and independent distributors.
IPO date
Feb 27, 2004
Employees
12,333
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT